Karen Foster Sells 96,923 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 96,923 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $20.15, for a total value of $1,952,998.45. Following the completion of the transaction, the insider directly owned 113,742 shares of the company’s stock, valued at $2,291,901.30. This represents a 46.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS traded up $0.04 during mid-day trading on Monday, hitting $19.90. 617,754 shares of the stock traded hands, compared to its average volume of 414,792. The company has a market cap of $961.17 million, a price-to-earnings ratio of -180.89 and a beta of 1.90. The stock has a fifty day moving average price of $23.37 and a 200-day moving average price of $25.07. BioLife Solutions, Inc. has a 52 week low of $19.10 and a 52 week high of $29.62.

Analyst Ratings Changes

A number of research analysts recently issued reports on BLFS shares. Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research note on Monday, December 29th. Finally, Northland Securities set a $34.00 price target on BioLife Solutions in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Amalgamated Bank boosted its position in shares of BioLife Solutions by 3.5% during the third quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock valued at $278,000 after buying an additional 366 shares during the last quarter. Ameritas Investment Partners Inc. raised its position in BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 441 shares during the last quarter. Louisiana State Employees Retirement System raised its position in BioLife Solutions by 2.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock worth $454,000 after buying an additional 500 shares during the last quarter. Isthmus Partners LLC lifted its stake in BioLife Solutions by 0.4% during the 2nd quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after acquiring an additional 509 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of BioLife Solutions by 2.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock valued at $447,000 after acquiring an additional 555 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.